【ChiCTR1800014521】The Feasibility and Effects of Smartphone-based Application on Cardiac Rehabilitation for Percutaneous Coronary Intervention Patients in Macau
ChiCTR1800014521
尚未开始
/
/
/
2018-01-18
/
/
冠心病
The Feasibility and Effects of Smartphone-based Application on Cardiac Rehabilitation for Percutaneous Coronary Intervention Patients in Macau
The Feasibility and Effects of Smartphone-based Application on Cardiac Rehabilitation for Percutaneous Coronary Intervention Patients in Macau
The objective of this study is to assess the feasibility and effectiveness of a mHealth application on cardiac rehabilitation (mCR), compared to usual CR care, among percutaneous coronary intervention (PCI) patients on the outcomes of: 1. Anxiety and depression level, by using the Chinese-Cantonese version of the Hospital anxiety and depression scale (HADS); 2. Medication adherence, by using pill count and medication taking record; 3. Exercise capacity, measure by 6-Minute Walk Test (6MWT); 4. Physical activity level, by using International Physical Activity Questionnaire in Chinese version (IPAQ-C); 5. Cardiovascular risk factors modification, including Bp, HR, body mass index (BMI), lipid profile, fasting blood glucose (FBG), HbA1C, smoking status and alcohol intake; 6. Self-efficacy, by the Cardiac Exercise Self-Efficacy Instrument in Chinese version (CESEI-C) and the Cardiac Diet Self-Efficacy Instrument in Chinese version (CDSEI-C); 7. Health-related quality of life (HRQL), by using the Chinese version of Cardiovascular Limitations and Symptoms Profile (C-CLASP); 8. Cardiac-related rehospitalization and Acute & Emergency Department (A&E) visit; and 9. CR App utility and satisfaction.
随机平行对照
治疗新技术
Permuted-blocked randomization, initiated by sequential numbers with variable block size of 4 in an opaque envelopes, will be conducted by a research assistant at the first week of discharge in the OPD. Participants will be allocated, to two groups: the experiment and control group
Build the outcome assessors, by research assistants.
Science and Technology Developmental Fundation of Macau (Fundo para o Desenvolvimento das Ciencias e da Tecnologia de Macau)
/
70
/
2017-12-01
2019-10-18
/
1) adult patients aged> 18 years-old with diagnosis of CHD; 2) be treated with PCI; 3) eligible to initiate phase I cardiac rehabilitation (CR) during hospitalization and able to continue phase II CR in Outpatient Department (OPD) rehabilitation centre, and 4) smartphone ownership.；
请登录查看1. Diagnosed with mental or psychiatric disorder; 2. high risk for CR according to American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) stratification guidelines (Research Proposal: Appendix III); 3. having repeated revascularization or Coronary Artery Bypass Graft; 4. significant physical exercise limitations other than heart disease, and 5. post cardiac devices implantation.；
请登录查看香港中文大學
/
香港中文大學的其他临床试验
- 治療無視野缺損性正常眼壓性青光眼（PNTG）的生活品質、療效和安全性:一項多中心隨機對照試驗
- 以環孢素眼藥水作為一線治療「非乾燥症而血清因子陽性的水液缺乏型乾眼症」的多中心隨機對照試驗
- 動作協調障礙兒童體育課中的內隱動作學習
- 一項前瞻性、單組介入研究：評估不含防腐劑交聯透明質酸和蘆薈眼藥水於白內障術後乾眼的療效
- 混合實境及沉浸式的神經認知眼科診斷 (MIND) 平台
- 青光眼中圖樣視網膜電圖之結構與功能整合
- 一种用于糖尿病视网膜病变定量病灶评估的眼动追踪注意感知强化学习算法
- 甲狀腺眼病患者外周免疫細胞譜
- 瞼板腺功能障礙的代謝組學研究
- Dissecting the role of gut microbiota in primary glaucoma patients through case-control and longitudinal cohort study
- 以理論為基礎的跨專業教育計劃，以提高香港華人社區長者的新冠疫苗接種率
- 復發性眼部單純疱疹病毒疾病患者的生活質素與病人自述結果：一項前瞻性橫斷面研究
- 正常眼壓青光眼疑似個案及視野缺損早期患者之眼壓藥物調整研究
- 使用生理和藥理方法調整眼瞼局部麻醉劑以改善手術止血效果和痛楚水平：雙盲隨機對照試驗
- Effects of nature-based mindfulness training on depression among adults with childhood adversity: A randomised controlled trial
- 一项关于合成益生菌制剂（SCM06）在儿童注意力缺陷多动障碍（ADHD）中疗效与安全性的预试验
- 网络心理支持平台对老年神经认知障碍和心理困扰护理人员的有效性研究
- Evaluation of the Effectiveness of the Enhanced 12-Session Caregiver Support Program - Shadowing the Golden Path 2.0
- 一项关于合生元配方 (MQU10) 在改善患有轻度至中度抑郁症状的成年人情绪和健康方面功效的初步研究
- 兒童阿托品抗藥性與近視發展機制之遺傳學研究
香港中文大學的其他临床试验
- 治療無視野缺損性正常眼壓性青光眼（PNTG）的生活品質、療效和安全性:一項多中心隨機對照試驗
- Feasibility, Acceptability and Effectiveness of a Tailored Multidimensional Intervention for Dementia Family Caregivers in Caregiving and Mental Health Crisis: A Pilot Randomised Controlled Trial
- One-step Rehydration Thawing Method in Frozen Embryo Transfer: A pragmatic randomized controlled clinical trial (ORT-FET-RCT)
- 以環孢素眼藥水作為一線治療「非乾燥症而血清因子陽性的水液缺乏型乾眼症」的多中心隨機對照試驗
- 動作協調障礙兒童體育課中的內隱動作學習
- Building Resilience Against Rising Temperature - The Effect of High-Intensity Interval Exercise (HIIE) on Heat Tolerance, Thermoregulatory Adaptation, and Physical Fitness: A Comparative Randomized Controlled Trial
- 一項前瞻性、單組介入研究：評估不含防腐劑交聯透明質酸和蘆薈眼藥水於白內障術後乾眼的療效
- 运动与脑刺激疗愈：促进居住于分间楼宇单位的注意力缺陷多动障碍儿童症状控制的三臂随机对照试验
- Effects of Care partner Online Programme for Managing BPSD and Enhancing Wellbeing (COPE‑BPSD)
- 混合實境及沉浸式的神經認知眼科診斷 (MIND) 平台
- Air purifier and respiratory outcomes in childhood asthma in compromised housing environments: a hybrid effectiveness-implementation trial
- 青光眼中圖樣視網膜電圖之結構與功能整合
- 一种用于糖尿病视网膜病变定量病灶评估的眼动追踪注意感知强化学习算法
- 甲狀腺眼病患者外周免疫細胞譜
- Young Adult Community Health Advisor (YACHA)-led Project to Promote Anti-drug Awareness among South Asian Youths and their Family in Hong Kong
- 瞼板腺功能障礙的代謝組學研究
- Dissecting the role of gut microbiota in primary glaucoma patients through case-control and longitudinal cohort study
- 以理論為基礎的跨專業教育計劃，以提高香港華人社區長者的新冠疫苗接種率
- 復發性眼部單純疱疹病毒疾病患者的生活質素與病人自述結果：一項前瞻性橫斷面研究
- 正常眼壓青光眼疑似個案及視野缺損早期患者之眼壓藥物調整研究
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04